Viking Therapeutics, Inc. (NASDAQ: VKTX ) has shrugged off the selling that came with a readout from its VENTURE-Oral study of VK2735, and has future catalysts ahead to improve or worsen sentiment. When I last wrote abou t the name, IScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure:I/we ...